Valeant’s Medicis Sues Anacor Over Research Collaboration

Valeant Pharmaceuticals International Inc. (VRX)’s Medicis unit, which makes drugs to treat skin conditions, sued Anacor Pharmaceuticals Inc. (ANAC) alleging violation of a collaborative research agreement.

Medicis wants a judge to force Anacor to comply with its contract and to issue “a permanent injunction against an improper arbitration,” according to papers filed in Delaware Chancery Court in Wilmington yesterday.

The complaint was filed under seal, with additional public information in other documents. Terms of the agreement weren’t specified. Palo Alto, California-based Anacor said in an Oct. 5 statement that it had a research-and-development agreement with Medicis to help discover small-molecule compounds to treat acne.

An Anacor spokeswoman, DeDe Sheel, didn’t immediately return a voice-mail message seeking comment on the dispute.

Valeant is based in Montreal, and Medicis is based in Scottsdale, Arizona.

The case is Medicis v. Anacor, CA8095, Delaware Chancery Court (Wilmington).

To contact the reporter on this story: Phil Milford at pmilford@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.